Optimized Chitosan–Lecithin Nanocarriers for Nose-to-Brain Delivery of Dalfampridine in Multiple Sclerosis: Box–Behnken Design Optimization, and Toxicity Evaluation
Journal of Pharmaceutical Innovation · 2026-08 · 21 (4)
DOI: 10.1007/s12247-026-10573-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Innovation, online erschienen am 12.04.2026. Verfasst von Jaghatha Therassama und 4 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Therassama, J., Edward, J. O. J., Arumugam, S., Pazhani, P., & Dharmian, J. P. (2026). Optimized Chitosan–Lecithin Nanocarriers for Nose-to-Brain Delivery of Dalfampridine in Multiple Sclerosis: Box–Behnken Design Optimization, and Toxicity Evaluation. Journal of Pharmaceutical Innovation, 21(4). https://doi.org/10.1007/s12247-026-10573-3
Vancouver
Therassama J, Edward JOJ, Arumugam S, Pazhani P, Dharmian JP. Optimized Chitosan–Lecithin Nanocarriers for Nose-to-Brain Delivery of Dalfampridine in Multiple Sclerosis: Box–Behnken Design Optimization, and Toxicity Evaluation. Journal of Pharmaceutical Innovation. 2026;21(4). doi:10.1007/s12247-026-10573-3
BibTeX
@article{Therassama2026,
author = {Therassama, Jaghatha and Edward, Justus Oliver Jaslin and Arumugam, Somasundaram and Pazhani, Pavazhaviji and Dharmian, Jose Prakash},
title = {Optimized Chitosan–Lecithin Nanocarriers for Nose-to-Brain Delivery of Dalfampridine in Multiple Sclerosis: Box–Behnken Design Optimization, and Toxicity Evaluation},
journal = {Journal of Pharmaceutical Innovation},
year = {2026},
volume = {21},
number = {4},
doi = {10.1007/s12247-026-10573-3}
}
EUVIMED